Concepedia

Publication | Open Access

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

DOIFull Paper Access

74

Citations

11

References

2020

Year

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi, Heinz Wiendl, Kenji P. Fujita, Fanny O’Brien, Heather Booth, James F. Howard, Claudio Mazia, Miguel Wilken,
Neurology

Abstract

This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo.

References

YearCitations

Page 1